TABLE 1.

The caveats that are listed on the PubMLST Neisseria website when interpreting the MenDeVAR Index^a

Parameter	Caveat(s) for both vaccines (unless otherwise stated)
Source of data	These data combine multiple sources of information, including peptide sequence identity through whole-genome sequencing, experimental assays developed as indirect measures of the breadth of vaccine protection against diverse meningococci, and assays developed to assess immunogenicity.
Protein expression	We have not inferred protein expression from genomic data; therefore, there may be isolates that possess genes but do not express the protein in vivo.
Cross-reactivity definition	An antigenic variant was considered cross-reactive if it had been tested in ≥5 isolates/subjects and was above the accepted threshold in ≥3/4 of those isolates. This was established through combined analysis of published experimental studies (PubMLST ID no. [PMID] provided for each variant), not from genomic data.
Meningococcal isolate source	These assays were based on serogroup B disease isolates for both vaccines.
Experimental assays
Bexsero	MATS assay
Trumenba	MEASURE assay, SBA assay
Age of vaccinees
Bexsero vaccine	For MATS assay development, Bexsero vaccine recipients were infants who had received 3 doses of vaccine and then a booster at 12 mo.
	The pooled sera used for the MATS assay were taken from the toddlers at 13 mo of age.
Trumenba vaccine	The age of vaccine recipients in the experimental studies varies widely, ranging from toddlers to adults, and needs to be taken into consideration when interpreting results.
	Vaccine studies used different schedules and doses of vaccines.

^aMenDeVAR, Meningococcal Deduced Vaccine Antigen Reactivity; MATS, meningococcal antigen typing system; MEASURE, meningococcal antigen surface expression; SBA, serum bactericidal activity.